Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1Phase 1 1

Status

Recruiting 3Active not recruiting 2

Sponsor Class

OTHER 3NIH 1INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 5Breast Neoplasms 5Neoplasms 3Neoplasm Metastasis 3Ovarian Neoplasms 2mCRPC 1Wilms Tumor 1Triple Negative Breast Neoplasms 1Stomach Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Pathologic Complete Response 1Pancreatic Neoplasms 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Hepatoblastoma 1Hemangiosarcoma 1Extensive Stage Lung Small Cell Carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 49enzalutamide 46apalutamide 36Specimen Handling 34Androgen Antagonists 30Abiraterone Acetate 29Radiosurgery 27Prednisone 26darolutamide 25Docetaxel 23Pluvicto 22abiraterone 20Radiotherapy 19Biopsy 17Leuprolide 15relugolix 11gallium 68 PSMA-11 11acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 11Surveys and Questionnaires 11Radiation 112-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 11Standard of Care 10Nivolumab 10cabazitaxel 9X-Rays 9Triptorelin Pamoate 9bicalutamide 8Carboplatin 8pembrolizumab 7olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Prostatic Neoplasms × talazoparib × 90 days × Clear all
NCT04550494 2026-05-13

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

National Cancer Institute (NCI)

Phase 2 Recruiting
36 enrolled
BreastGastrointestinalGenitourinaryGynecologic

Breast Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms

NCT04846478 2026-05-12

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
35 enrolled
Genitourinary

Prostatic Neoplasms

NCT05873192 2026-05-05

Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Recruiting
30 enrolled
Genitourinary

Prostatic Neoplasms

NCT06844383 2026-04-24

TALENT

Prostate Cancer Clinical Trials Consortium

Phase 2 Recruiting
126 enrolled
Genitourinary

Adenocarcinoma, Prostatic Neoplasms

NCT04821622 2026-04-07

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Pfizer

Phase 3 Active not recruiting
599 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡